Uncategorized
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth’s Optum Rx Formularies
Vertex’s Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales. read more
4 Bitcoin Stocks Set For Growth: Analyst Highlights High-Performance Computing As Key Catalyst
Rosenblatt analyst Chris Brendler initiated coverage of Bitcoin stocks on Friday, citing a premium likely for the stocks due to their entry into the high-performance computing (HPC) business. Latest Ratings for HIVE Date Firm Action From To Jun 2021 HC Wainwright & Co. Initiates Coverage On Buy Jun 2019 Craig-Hallum Downgrades Buy Hold May 2017…